Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: The Company operates a telemedicine platform selling men's wellness products (ED, hair loss, testosterone, weight management) under brands such as Mango, Grow, Mojo, and Slim. It also markets FDA-approved oral testosterone (Prime). The Company is a smaller reporting company and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenues | $68,757 | $136,621 |
| Net Loss | $(1,312,931) | $(4,716,072) |
| Loss Per Share (Basic & Diluted) | $(0.09) | $(0.32) |
| Cash and Cash Equivalents | $228,688 | $228,688 |
| Total Assets | $14,172,795 | $14,172,795 |
| Total Liabilities | $1,648,969 | $1,648,969 |
| Working Capital | $(1,152,376) | $(1,152,376) |
| Accumulated Deficit | $(45,363,283) | $(45,363,283) |
Key Balance Sheet Items:
- Intangible Assets: $13,646,570 (primarily acquired patents and licenses).
- Current Liabilities: $1,398,063, including $889,733 in accounts payable and $275,000 in deposit/contract liability related to a pending transaction.
- Related Party Debt: $44,944 in notes payable to related parties.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 59% for the three months ended June 30, 2026 ($68,757) compared to the same period in 2025 ($168,109), attributed to a focus on in-house website development and testing of new products prior to full launch.
- Net Loss Reduction: Net loss improved significantly, decreasing by 76% for the three months ended June 30, 2026 compared to the prior year period. This was driven by substantial reductions in stock-based compensation ($92,417 vs. $3,120,445), investor relations expenses ($0 vs. $106,000), and general and administrative costs.
- Cash Position: Cash and cash equivalents decreased by approximately $1.26 million during the six-month period, primarily due to operating losses and limited fundraising activity.
- Stock-Based Compensation: Significant decrease in stock-based compensation expense due to fewer shares issued for services and reduced option vesting compared to the prior year.
Guidance, Outlook, Risks, and Unusual Items
Business Combination Agreement (BCA): On July 29, 2026 (subsequent to the period end), the Company entered into a BCA with Nuclea Energy Inc. The transaction involves a reverse merger where Nuclea shareholders would hold approximately 96% of the combined company's equity. The deal is contingent on a minimum $15 million PIPE financing, shareholder approval, and Nasdaq approval. Current CEO Jacob D. Cohen is set to resign as CEO and become President upon closing, receiving a severance package including $1.5 million cash and 2 million shares.
Liquidity and Going Concern: The Company has a working capital deficit of approximately $1.2 million and an accumulated deficit of $45.4 million. Management states that current capital resources are insufficient to fund operations for the next 12 months. The filing includes a "Going Concern" warning, noting that the Company must raise additional capital through equity or debt, which may result in significant dilution.
Regulatory and Listing Risks:
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00/share). It has been granted a second compliance period until February 1, 2027, to regain compliance, potentially via a reverse stock split.
- FDA/Compounding Risks: The Company relies on a related-party pharmacy for compounded products under Section 503A of the FFD&C Act. There is a risk that the FDA may determine these activities constitute manufacturing rather than compounding, leading to enforcement actions.
Legal Proceedings:
- Boustead Arbitration: Boustead Securities is claiming over $1 million in fees for services not rendered; the Company intends to vigorously defend.
- Clarity Ventures Lawsuit: The Company filed a lawsuit against a former technology firm seeking over $73 million in damages for failure to deliver a compliant platform.
Investor Verification Checklist
- Transaction Viability: Verify the status of the $15 million PIPE financing required for the Nuclea Energy merger and the likelihood of Nasdaq approval given the current stock price.
- Cash Runway: Confirm the timeline for raising additional capital given the $228,688 cash balance and $1.2 million working capital deficit.
- Dilution Impact: Assess the impact of the proposed merger (96% ownership for Nuclea shareholders) and potential future equity issuances on existing shareholders.
- Nasdaq Status: Monitor the Company's ability to maintain the $1.00 minimum bid price or successfully execute a reverse stock split before the February 1, 2027 deadline.
- Related Party Transactions: Review the terms of the related-party pharmacy (Epiq Scripts) and loans from the CEO's trust (Tiger Cub) for potential conflicts of interest.